2025 Hyper Recent •CC0 1.0 Universal

This work is dedicated to the public domain. No rights reserved.

Access Preprint From Server
January 22nd, 2025
Version: 1
Medical Univeristy of Vienna
cancer biology
biorxiv

Enhanced AkaLuc Bioluminescence Imaging for Longitudinal Intravital Monitoring of Minimal Residual Disease in a Murine Model of Triple-negative Breast Cancer

Steinbauer, S.Open in Google Scholar•Cowles, J. D.Open in Google Scholar•Sabbaghi, M. A.Open in Google Scholar•Poppelaars, M.Open in Google Scholar•Hussain, A.Open in Google Scholar•Wagesreither, M.Open in Google Scholar•Laimer-Gruber, D.Open in Google Scholar•Tovari, J.Open in Google Scholar•Szakacs, G.Open in Google Scholar•Csiszar, A.Open in Google Scholar

Triple-negative breast cancer (TNBC) is an aggressive form of cancer with poor prognosis. Beyond the absence of targeted therapies, a major challenge is its high recurrence rate, driven by the outgrowth of residual tumor cells that survive chemotherapy and persist during minimal residual disease (MRD). To monitor the therapy response of TNBC by enhanced intravital imaging, we established a clinically relevant combination chemotherapy protocol for the treatment of mouse mammary tumors engrafted from K14cre;Brca1F/F;Trp53F/F (KB1P) organoids engineered to express an mCherry-AkaLuc dual reporter (mCA-KB1P). Reproducible MRD and relapse response patterns with significantly extended relapse-free survivals were achieved with the TAC protocol, consisting of docetaxel, doxorubicin and cyclophosphamide. AkaLuc bioluminescence imaging (AkaBLI) of mCA-KB1P organoids verified the single-cell sensitivity of the system in vitro, and showed a detection limit of approximately 1000 cells in the mammary gland of living mice. Unexpectedly, mCA-KB1P organoids elicited an immune response, which necessitated the use of immunodeficient hosts for the longitudinal intravital monitoring of MRD. AkaBLI and an adapted TAC protocol enabled, for the first time, the non-invasive intravital tracking and an estimation of the number of surviving tumor cells in the MRD state following intensive chemotherapy. Engineering KB1P organoids for Histon2B-mCherry reporter expression (HmC-KB1P) enabled the estimation of tumor cell survival also in syngeneic immunocompetent hosts. Flow cytometry and histological analysis revealed that immunocompetent hosts harbored only a few residual cells at MRD, which exhibited a transient loss of epithelial characteristics, whereas immunodeficient hosts had a greater number of surviving cells with a maintained epithelial phenotype. These findings are consistent with a role of the immune system in shaping phenotypic changes influencing survival following chemotherapy. Together, the results demonstrate the utility of the AkaBLI system for rare tumor cell tracking and highlight the role of the immune system in triggering adaptive responses to chemotherapy.

Similar Papers

biorxiv
Thu May 08 2025
Synergistic targeting of cancer cells through simultaneous inhibition of key metabolic enzymes
As cancer cell specific rewiring of metabolic networks creates potential therapeutic opportunities, we conducted a synthetic lethal screen utilizing inhibitors of metabolic pathways. Simultaneous administration of (R)-GNE-140 and BMS-986205 (Linrodostat) preferentially halted proliferation of ovarian cancer cells, but not of their non-oncogenically transformed progenitor cells. While (R)-GNE-140 i...
Dreute, J.
•
Stengel, J.
•
Becher, J.
•
van den Borre, D. R.
...•
Schmitz, M. L.
biorxiv
Thu May 08 2025
Loss of ATG5 expression in a subset of human prostate cancers promotes tumor growth through accumulation of p62
Loss-of-function mutations in autophagy-related (ATG) genes are rare in cancer. However, we report herein that ATG5 is fully deleted in ~14% of prostate cancers (PCa), rivaling that of well-established tumor suppressor genes. ATG5 expression was downregulated at both mRNA and protein levels and was associated with poor patient survival. The DU145 PCa cell line, isolated from a brain metastasis, is...
Wible, D. J.
•
Li, W.
•
Liu, X.
•
Sebastian, M. M.
...•
Bratton, S. B.
biorxiv
Thu May 08 2025
WITHDRAWN: Oncostratifier: Stratifying Oncogene-addicted Cohorts By Drug Response
Oncogenes, when mutated or overexpressed, drive tumorigenesis and can lead to oncogene addiction, where cancer cells rely on such genes for survival and proliferation. Stratifying oncogene-addicted cohorts is essential to uncover alternative therapeutic avenues, for instance in cases of untargetable oncogenes or resistance to treatment. We propose Oncostratifier, a framework to identify drugs that...
Tepeli, Y. I.
•
Trastulla, L.
•
Goncalves, J. P.
•
Iorio, F.
biorxiv
Thu May 08 2025
Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for AML cell self-renewal.
DNA hypomethylating agents (HMAs) are used to treat acute myeloid leukemia (AML) and myelodysplasia patients who are unsuitable for intensive chemotherapy. However, low response rates and therapy-resistant relapse remain significant challenges. To improve outcomes, we must understand how AML cells survive HMA treatment and continue to proliferate following therapy. We combine single-cell multiomic...
Bond, D. R.
•
Burnard, S. M.
•
Uddipto, K.
•
Hunt, K. V.
...•
Lee, H. J.
biorxiv
Thu May 08 2025
Metabolic modulation of intratumoral cholesterol with gut microbiota for the treatment of colorectal cancer
Excess cholesterol is positively correlated with colorectal cancer (CRC). Current therapeutic strategies for modulating cholesterol levels in CRC are limited and often come with complications. Here, we demonstrated that microbiome shunting of intestinal cholesterol to anticancer metabolites is a safe and applicable therapeutic approach for CRC. By screening major microbial metabolic products of ch...
Wu, J.
•
Lai, Y.
•
Li, J.
•
Zhai, L.
...•
Wong, H. L. X.
biorxiv
Thu May 08 2025
Plasma Exosomes in Insulin Resistant Obesity Exacerbate Progression of Triple Negative Breast Cancer
Breast cancer, the most common cancer among women worldwide, continues to pose significant public health challenges. Among the subtypes of breast cancer, triple-negative breast cancer (TNBC) is particularly aggressive and difficult to treat due to the absence of receptors for estrogen, progesterone, or human epidermal growth factor receptor 2, rendering TNBC refractory to conventional targeted the...
Llevenes, P.
•
Chen, A.
•
Lawton, M. L.
•
Rondon-Ortiz, A. N.
...•
Denis, G. V.
biorxiv
Wed May 07 2025
Miro1 knockout inhibits mouse breast cancer tumorigenesis
Miro1 is a mitochondrial outer membrane protein that regulates mitochondrial and peroxisome trafficking, endoplasmic reticulum (ER) association, and mitophagy. Prior studies suggest a role for Miro1 in cell migration and proliferation in both normal and tumor cells. High Miro1 expression is associated with poor overall survival in breast cancer patients. To investigate the role of Miro1 in breast ...
Termos, R.
•
Muskat, A.
•
Shannon, N.
•
McCoy, M.
...•
Cunniff, B.
biorxiv
Wed May 07 2025
IRE1α and IRE1β Protect Intestinal Epithelium and Suppress Colorectal Tumorigenesis through Distinct Mechanisms
Intestinal epithelial cells (IECs) uniquely express two IRE1 paralogues, IRE1 and IRE1{beta}, whose roles in intestinal physiology are incompletely understood. We examined the individual and cooperative functions of IRE1 and IRE1{beta} in IECs using mice using intestine-specific deletion of Ire1 or germline Ire1{beta} deletion, and subsequently with double deleted Ire1, Ire1{beta} mice. At baselin...
Deng, R.
•
Wang, M.
•
Promlek, T.
•
Druelle-Cedano, C.
...•
Kaufman, R. J.
biorxiv
Wed May 07 2025
Integrated single cell spatial multi-omics landscape of WHO grades 2-4 diffuse gliomas identifies locoregional metabolomic regulators of glioma growth
Diffuse infiltrating gliomas are aggressive tumors of the central nervous system driven by intra-tumoral heterogeneity and aberrant normal-tumor cell-cell interactions. Grade specific and locoregional metabolic dependencies driving aberrant cell-states linked to treatment resistance, seizures and infiltration of gliomas remain elusive. Here, we applied spatial transcriptomics (stRNAseq), imaging m...
Ma, Y.
•
Ayadhury, S.
•
Singh, S.
•
Vashishath, Y.
...•
Ene, C. I.
biorxiv
Wed May 07 2025
Insights into gallbladder cancer pathogenesis from a living organoid gallbladder cholangiocyte biorepository
Gallbladder cancer (GBC) while rare worldwide has a high prevalence in India. Pathogenesis is unclear and outcomes poor. Gallbladder cholangiocyte organoids (GCOs) or gallbladder carcinoma organoids (GBCOs) were developed and serially propagated from surgically resected gallbladder tissues with benign or malignant diseases, respectively. Patient derived organoids (PDOs) were derived from 15 normal...
Dutta, A.
•
Chowdhury, N.
•
Selvarajan, A. V.
•
Banerjee, P.
...•
GuhaSarkar, D.